Literature DB >> 17356191

Selective abolition of the vestibular-ocular reflex by sedative drugs.

Sarah Anne Morrow1, G Bryan Young.   

Abstract

INTRODUCTION: The vestibulo-ocular reflex (VOR) is an important part of the neurological examination of the patient with coma when determining brainstem function. VOR is tested via the oculocephalic reflex (OCR) and the oculovestibular reflex (OVR), or cold calorics. It has been noted that sedative medications, such as opioids and benzodiazepines, can diminish or abolish the VOR.
METHODS: We performed a chart review on three patients noted to have absent VOR at initial neurological assessment as an isolated finding.
RESULTS: The three patients ranged in age from 45-74 years. Two patients presented with intentional drug overdoses, whereas the third patient had a complicated course postcardiac surgery and received sedative drugs. All three patients initially had absent responses to OCR and cold calorics bilaterally. However, all other brainstem functions were normal at the initial examination. All three patients regained both OCR and OVR within 24 hours after sedative medication had been removed.
CONCLUSION: Sedatives may selectively and transiently abolish the VOR, altering the clinical examination; this is to be considered in the examination of a patient with coma.

Entities:  

Mesh:

Year:  2007        PMID: 17356191     DOI: 10.1385/NCC:6:1:45

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  17 in total

Review 1.  Assessment: vestibular testing techniques in adults and children: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  T D Fife; R J Tusa; J M Furman; D S Zee; E Frohman; R W Baloh; T Hain; J Goebel; J Demer; L Eviatar
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

Review 2.  Vertigo.

Authors:  R J Tusa
Journal:  Neurol Clin       Date:  2001-02       Impact factor: 3.806

3.  Spontaneous synaptic activity is primarily GABAergic in vestibular nucleus neurons of the chick embryo.

Authors:  Mei Shao; June C Hirsch; Christian Giaume; Kenna D Peusner
Journal:  J Neurophysiol       Date:  2003-08       Impact factor: 2.714

Review 4.  Primary neurotransmitters and regulatory substances onto vestibular nucleus neurons.

Authors:  M Sasa; S Takeshita; T Amano; K Kurisu
Journal:  Biol Sci Space       Date:  2001-12

5.  Neurotoxic effect of lead at low concentrations.

Authors:  O Mameli; M A Caria; F Melis; A Solinas; C Tavera; A Ibba; M Tocco; C Flore; F Sanna Randaccio
Journal:  Brain Res Bull       Date:  2001-05-15       Impact factor: 4.077

6.  Reliability of the vestibulo-ocular reflex as an index of the effects of hypnotic drugs on the central nervous system.

Authors:  E L Cerchiari; D Carugo; T Della Puppa; A Ravizza
Journal:  Br J Anaesth       Date:  1984-04       Impact factor: 9.166

7.  Modulation of vestibular function by nociceptin/orphanin FQ: an in vivo and in vitro study.

Authors:  M R Sulaiman; M Niklasson; R Tham; M B Dutia
Journal:  Brain Res       Date:  1999-05-15       Impact factor: 3.252

Review 8.  Transdermal therapeutic fentanyl-system (TTS-F).

Authors:  Kyriaki Mystakidou; Emmanuela Katsouda; Eleni Tsilika; Efi Parpa; Lambros Vlahos
Journal:  In Vivo       Date:  2004 Sep-Oct       Impact factor: 2.155

9.  Betahistine increases vestibular blood flow.

Authors:  J K Dziadziola; E L Laurikainen; J D Rachel; W S Quirk
Journal:  Otolaryngol Head Neck Surg       Date:  1999-03       Impact factor: 3.497

10.  Evidence for inhibition mediated by coassembly of GABAA and GABAC receptor subunits in native central neurons.

Authors:  Carol J Milligan; Noel J Buckley; Maurice Garret; Jim Deuchars; Susan A Deuchars
Journal:  J Neurosci       Date:  2004-08-18       Impact factor: 6.167

View more
  1 in total

1.  Loss of Vestibular Ocular Reflex in Nonconvulsive Status Epilepticus.

Authors:  Jennifer H Kang; Aatif M Husain; Joel C Morgenlander
Journal:  Neurocrit Care       Date:  2019-06       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.